微小RNA-30c在肾癌组织中的表达及其临床意义

目的   探讨微小RNA-30c（miR-30c）在肾癌组织中的表达及其临床病理特征和预后关系。方法   收集本院2012年1月至2015年12月经手术切除的95例肾癌组织和82例癌旁组织标本，采用实时定量PCR（QPCR）检测以上组织中miR-30c水平，分析miR-30c表达与肾癌临床病理参数（性别、年龄、TNM分期、淋巴结转移、远处转移和T分期）及预后的关系，采用Cox回归模型进行多因素分析。结果  QPCR检测发现95例肾癌组织中miR-30c的表达水平为0.561±0.378，低于82例癌旁组织的1.220±0.820（P＜0.05）。肾癌组织中miR-30表达与性别、远处转移和年龄均无关（P＞0.05），而与TNM分期、淋巴结转移和T分期均有关（P＜0.05），其中Ⅲ～Ⅳ期、淋巴结转移及T3～T4期的miR-30c相对表达量分别为0.422±0.219、0.442±0.299和0.408±0.194，均低于Ⅰ～Ⅱ期、无淋巴结转移及T1～T2期的0.671±0.439、0.619±0.400和0.654±0.431（P＜0.05）；Ⅲ～Ⅳ期、淋巴结转移及T3～T4期的miR-30c高表达率分别为21.43％（9／42）、16.13％（5／31）和19.44％（7／36），均低于Ⅰ～Ⅱ期、无淋巴结转移及T1～T2期的41.51％（22／53）、16.13％（26／64）和40.68％（24／59），差异均有统计学意义（P＜0.05）。miR-30c低表达组的中位总生存期为37.0个月，短于高表达组（＞60.0个月），差异有统计学意义（P＜0.05）。Cox回归模型分析发现，TNM分期、淋巴结转移、远处转移、T分期及miR-30c表达均是影响预后的独立因素。结论   肾癌组织中miR-30c低表达，miR-30c参与肾癌的发生发展且与预后有关，其中miR-30c低表达者的预后较差，是影响预后的独立因素。

Expression of microRNA-30c in renal cell carcinoma and its clinical significance

Objective To investigate the expression of microRNA-30c （miR-30c） in renal cell carcinoma and its relationship with clinicopathological features and prognosis. Methods Ninety-five cases of surgical removed renal cell carcinoma tissues and 82 cases of paracancerous tissues from January 2012 to December 2015 were collected. Real-time quantitative PCR （QPCR） was used to detect the level of miR-30c in the above tissues. The relationship between miR-30c expression and clinicopathological parameters （gender， age， TNM stage， lymph node metastasis， distant metastasis and T staging） and prognosis of renal cell carcinoma were analyzed. Cox regression model was used for multivariate analysis. Results QPCR detection showed that the expression level of miR-30c in 95 cases of renal cell carcinoma was 0.561±0.378， lower than 1.220±0.820 in 82 cases of adjacent tissues （P＜0.001）. The expression of miR-30 in renal cell carcinoma was not related to sex， age and distant metastasis （P＞0.05）， but related to TNM stage， lymph node metastasis and T stage （P＜0.05）. The relative expressions of miR-30c in Ⅲ-Ⅳ stage， lymph node metastasis and T3-T4 stage were 0.422±0.219， 0.442±0.299 and 0.408±0.194， lower than 0.671±0.439， 0.619±0.400 and 0.654±0.431 in Ⅰ-Ⅱ stage， no lymph node metastasis and T1-T2 stage （P＜0.05）. The high expression rates of miR-30c in Ⅲ-Ⅳ stage， lymph node metastasis and T3-T4 stage were 21.43％（9／42）， 16.13％（5／31） and 19.44％（7／36）， lower than 41.51％（22／53）， 16.13％（26／64） and 40.68％（24／59） of Ⅰ-Ⅱ stage， no lymph node metastasis and T1-T2 stage （P＜0.05）. The median overall survival of miR-30c expression in the low level group was 37.0 months， which was significantly shorter than that in the high level group （＞60.0 months）， and the difference was statistically significant （P＜0.05）. Cox regression analysis showed that TNM stage， lymph node metastasis， distant metastasis， T stage and miR-30c expression were independent prognostic factors of renal cell carcinoma. Conclusion The low expression of miR-30c in renal carcinoma is involved in the development of renal cancer and is related to the prognosis. The prognosis of low expression of miR-30c is poor， and the level of miR-30c is an independent factor affecting the prognosis.